|
 |
GlumetzaThis page contains recent news articles, when available, and an overview of Glumetza but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Lupin, in its certification notice, said that the said US Patents listed in the FDA Orange Book for Glumetza by Depomed are invalid and/or will not be ... pharmabiz.com Santarus Submits IND for Phase III Clinical Testing of Rifamycin SV MMX in ... - Dec 31, 2009 Santarus® and ZEGERID® are registered trademarks of Santarus, Inc.GLUMETZA® is a registered trademark of Biovail Laboratories International Srl licensed ... PharmiWeb.com (press release) Santarus Announces Webcast Presentation at the Lippert/Heilshorn Life Sciences ... - Dec 14, 2009 Santarus ® and ZEGERID ® are registered trademarks of Santarus, Inc. GLUMETZA ® is a registered trademark of Biovail Laboratories International Srl licensed ... Behavioral Health Central (blog) Santarus Receives Previously Announced $20 Million Milestone for FDA Approval ... - Dec 22, 2009 Santarus(R), ZEGERID(R) and ZEGERID OTC(TM) are trademarks of Santarus, Inc. GLUMETZA(R) is a registered trademark of Biovail Laboratories International Srl ... FOXBusiness Sign Up For Our Free Newsletter!! AGRT,ACTG,ZAGG,SNTS,CTIC,BLDP - Dec 22, 2009 ...which is indicated for the treatment of certain upper GI diseases and disorders, and on GLUMETZA(R) (metformin hydrochloride extended release tablets), ... TMC Net Market Report -- In Play (DEPO) - Nov 10, 2009 Lupin's certification notice alleges that Depomed's US Patents listed in the FDA Orange Book for GLUMETZA are invalid and/or will not be infringed by ... MSN Money Santarus to Present at Lazard Capital Markets 6th Annual Healthcare Conference - Nov 10, 2009 Santarus ® and ZEGERID ® are registered trademarks of Santarus, Inc. GLUMETZA ® is a registered trademark of Biovail Laboratories International Srl licensed ... WELT ONLINE Depomed Reports Third Quarter 2009 Financial Results - Oct 29, 2009 Revenue for the three months ended September 30, 2008 included a one-time recognition of $6.3 million in product sales of GLUMETZA related to previously ... Reuters Santarus Inc. Q3 2009 Earnings Call Transcript - Nov 4, 2009 Product related revenue in the current quarter included $31.5 million in ZEGERID net product sales and $6.8 million earned under our Glumetza promotion ... Seeking Alpha (blog) Top Performer for Wed: Santarus (SNTS) - Nov 11, 2009 Its efforts are focused on ZEGERID® for the treatment of certain upper GI diseases and disorders, and GLUMETZA® to improve glycemic control in adults with ... Zacks.com Santarus Reports Strong Quarter - Nov 9, 2009 Glumetza total prescriptions increased 9.2% on a sequential basis. License fee and royalty payments declined to $2 million in the third quarter of 2009, ... Zacks.com Santarus Ranked Number 23 Fastest Growing Company in North America on Deloitte ... - Oct 20, 2009 Santarus® and ZEGERID® are registered trademarks of Santarus, Inc.GLUMETZA® is a registered trademark of Biovail Laboratories International Srl licensed ... Reuters Santarus reports Q3 net income - Nov 6, 2009 ..."Our decision to increase financial guidance was due to our strong third quarter financial performance, including Zegerid and Glumetza revenue growth, ... Behavioral Health Central (blog) Depomed Q3 Financial Results (NASDAQ:DEPO) - Oct 30, 2009 Depomed's GLUMETZA (metformin hydrochloride extended release tablets) has already been approved for use in adults with Type 2 diabetes and the prescriptions ... FavStocks (blog) Depomed to Present at Merriman Curhan Ford`s Investor Summit 2009 - Nov 3, 2009 GLUMETZA(R) (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, ... Reuters High Flyers: RSTI, MEND, SNTS - Nov 5, 2009 The SNTS brand Zegerid had approximate total prescriptions of 294000 in Q3 09 (a 6.3% increase over Q3 08) and its Glumetza brand had approximate total ... Small Cap Network Other News To Note - Nov 10, 2009 ...advising Depomed of the filing of an abbreviated new drug application with the FDA for a generic version of Glumetza (metformin) in 500-mg and 1000-mg ... Therapeutics Daily (press release) (registration) Serada Half Price Sale: DepoMed's Stock Price Poised to Climb - Nov 8, 2009 Finally, Glumetza, DepoMed's once-a-day metformin product, is now the best-selling branded metformin product. Clearly, there was a mass exodus following the ... Seeking Alpha (blog) Depomed, Inc. to Announce Third Quarter 2009 Financial Results on October 29, 2009 - Oct 22, 2009 GLUMETZA(R) (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, ... Reuters Depomed, Inc. - Medical Equipment - Deals and Alliances Profile - new report ... - Nov 10, 2009 Currently, the company has two commercialized products include GLUMETZA and ProQuin. The company is headquartered at Menlo Park, in California, ... PR-Inside.com (Pressemitteilung) Up-Trend Outlook: RCRC, ANAD, DEPO, MOVE - Oct 21, 2009 In the DEPO product line is GLUMETZA for the treatment of type 2 diabetes and Proquin XR for treatment of uncomplicated urinary tract infection. ... Small Cap Network Santarus Ranked Number 23 Fastest Growing Company in North America on ... - Oct 20, 2009 Santarus(R) and ZEGERID(R) are registered trademarks of Santarus, Inc. GLUMETZA(R) is a registered trademark of Biovail Laboratories International Srl ... Trading Markets (press release) NASDAQ - Depomed, Inc. to Announce Third Quarter 2009 Financial Results on ... - Oct 22, 2009 GLUMETZA (R) (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, ... Ad-Hoc-News (Pressemitteilung) End of Deal Is a Plus | TheStreet.com Stocks Under $10 News | Print … - Dec 14, 2005 DepoMed (DEPO:Nasdaq) and Biovail (BVF:Amex) reached an agreement last night to revert US marketing rights to DepoMed's diabetes treatment, Glumetza, ... TheStreet.com - TheStreet.com (subscription) Depomed says FDA approves 1000 mg strength tablets of Glumetza - Jan 2, 2008 Jan 2 (Reuters) - Depomed Inc (DEPO.O) said US health regulators have approved the 1000 mg strength tablets of Glumetza for patients with type 2 diabetes. ... Reuters New Once-Daily Oral Diabetes Treatment Glumetza(TM) Now Available - Sep 6, 2006 Adult patients living with type 2 diabetes now have a new treatment option available that may help them get the most out of their care. ... RedOrbit Depomed, King terminate diabetes drug deal - Oct 29, 2007 N) said on Monday they terminated their promotion agreement for Glumetza, ... 31, but King will fulfill its Glumetza promotion obligations through the end ... Reuters … and Depomed Announce US Promotion Agreement for GLUMETZA … - Jul 22, 2008 Santarus expects to train its field sales representatives in the third quarter and to begin promotion of GLUMETZA brand products in the fourth quarter of ... RedOrbit Health Canada Approves Glumetza (Metformin) to Treat Type II Diabetes - Jun 1, 2005 TORONTO, ON -- June 1, 2005 -- Biovail Corporation BVF (TSX:BVF) and Depomed, Inc. DEPO announced today that the Therapeutic Products Directorate Canada ... DG News … and Depomed Announce Agreement to Co-Promote Glumetza(TM) - Jun 28, 2006 Glumetza(TM) is a once-daily extended-release formulation of metformin for the treatment of patients with Type II diabetes that Depomed developed utilizing ... Genetic Engineering News - Genetic Engineering News (press release) Diabetes Drug Glumetza Gets Approvable Letter From FDA - Mar 2, 2005 By Aaron Lorenzo. The FDA issued an approvable letter for Glumetza, a once-daily, extended-release version of the diabetes drug metformin, ... BioWorld Online - BioWorld Online King's Profits Decline | Pharmaceuticals News | Print Financial &... - Nov 9, 2006 King expects sales in the near future to be aided by the early September launch of Glumetza, a once-a-day, blood-sugar control drug that it's co-promoting ... TheStreet.com - TheStreet.com (subscription) Santarus Commences GLUMETZA Promotion - Oct 10, 2008 Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, today announced that it has commenced promotion of GLUMETZA(R) (metformin hydrochloride ... RedOrbit Depomed wins 2nd FDA approval Menlo Park firm to issue slow-release … - Jun 4, 2005 The lower dose of Glumetza is enclosed in Depomed's swelling pill, which expands in water and keeps the tablet from quickly passing from the stomach to the ... San Francisco Chronicle Wednesday's Health Stock Winners & Losers - Jun 28, 2006 ...company said it entered an agreement with King Pharmaceuticals (KG - commentary - Cramer's Take) to market its once-a-day type 2 diabetes drug Glumetza. ... TheStreet.com - TheStreet.com (subscription) … Prior Approval Supplement for 1000 Mg Strength Tablets of Glumetza - Apr 2, 2007 Glumetza may be used concomitantly with a sulfonylurea or insulin to improve ... Glumetza is contraindicated in patients with renal disease or renal ... RedOrbit Depomed, Biovail Update Status of Glumetza NDA - Apr 13, 2005 Depomed, Inc. (NASDAQ:DEPO) and Biovail Corporation (NYSE:BVF)(TSX:BVF) today announced that a response has been submitted to the United States Food and ... RedOrbit … Canadian Commercial Availability of 1,000mg Dosage of Glumetza(TM). - Jan 24, 2008 The features and benefits of Glumetza[TM] 1000mg, which received a Notice ... Glumetza[TM] may be used as monotherapy, or concomitantly with a sulfonylurea. ... Free with registration - Business Wire - AccessMyLibrary.com … and King Pharmaceuticals Prepare for Launch of Glumetza(TM) as... - Aug 23, 2006 MENLO PARK, Calif. & BRISTOL, Tenn. -- Depomed, Inc. (NASDAQ:DEPO) and King Pharmaceuticals, Inc. (NYSE:KG) announced today that as they prepare for the ... Free with registration - Business Wire - AccessMyLibrary.com … approvable letter from FDA for extended-release Glumetza for Type... - Mar 1, 2005 The letter indicated that Glumetza is approvable pending the completion of discussions ... Biovail's NDA for Glumetza in 500 mg and 1000 mg dosage forms, ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com Depomed to borrow $15 million for hot flash drug - Jun 30, 2008 The company already has two drugs on the market -- Glumetza, for type 2 diabetes, and Proquin XR for urinary tract infections. ... Bizjournals.com … Glycemic Control in Patients with Type 2 Diabetes with Glumetza/Sul... - Jun 7, 2006 The data demonstrated that adding Glumetza, an FDA-approved, ... "This is very important data that further support Glumetza as a potential first line choice ... Genetic Engineering News - Genetic Engineering News (press release) … ; FDA grants approvable letter for extended-release Glumetza for... - Apr 3, 2005 The letter indicated that Glumetza is approvable pending the completion of ... Biovail's NDA for Glumetza - in 500mg and 1000mg dosage forms - was filed ... Pay-Per-View - Medical Letter on the CDC & FDA - Factiva, from Dow Jones Depomed asks for new Glumetza approval - Apr 2, 2007 By : Agencies. MENLO PARK, Calif. (AP) - Drug developer Depomed Inc. said Monday it asked the Food and Drug Administration to approve a new 1000-milligram ... ABCmoney.co.uk … Patient Support Program Offers Savings on Glumetza(TM) Therapy for... - Nov 21, 2006 King Pharmaceuticals, Inc. (NYSE: KG) and Depomed, Inc. (NASDAQ: DEPO) today announced the launch of a new program that will provide support for patients ... Genetic Engineering News - Genetic Engineering News (press release) … ; FDA grants approvable letter for extended-release Glumetza for... - Mar 28, 2005 The letter indicated that Glumetza is approvable pending the completion of ... Biovail's NDA for Glumetza - in 500mg and 1000mg dosage forms - was filed ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones Q2 2007 DepoMed Earnings Conference Call - Final. - Aug 7, 2007 First, we continue to be encouraged by the recent trends in Glumetza scripts. ... Beginning with Glumetza, we continue to work very closely with our US ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com BIOVAIL LAUNCHES GLUMETZA TO CANADIAN PHYSICIANS. - Jan 1, 2006 Developed in partnership with Depomed, Inc. (NASDAQ:DEPO) of Menlo Park, California, Glumetza(TM) is the first once-daily, extended-release formulation of ... Free with registration - Worldwide Biotech - AccessMyLibrary.com Santarus Reports Third Quarter 2008 Financial Results - Nov 3, 2008 ..."Our sales force has begun promoting GLUMETZA(R) for the treatment of ... We anticipate the addition of GLUMETZA will be accretive in 2009 and beyond." ... Genetic Engineering News - Genetic Engineering News (press release) … Non-Binding Term Sheet Agreement With Biovail for Glumetza - Nov 23, 2005 In addition, regulatory applications for once daily Glumetza(TM) (Metformin GR(R)) for the treatment of Type II diabetes have been approved in the US and ... RedOrbit Depomed Reports 2006 Year End Financial Results - Mar 14, 2007 In addition, $526000 was in product sales of Glumetza(TM) (metformin hydrochloride extended release tablets) through King Pharmaceuticals and $109000 was ... Genetic Engineering News - Genetic Engineering News (press release) Biovail Launches 1,000mg Glumetza in Canada - Jan 28, 2008 Biovail has reported the Canadian launch of 1000mg dosage strength of Glumetza, a once-daily, extended-release formulation of metformin hydrochloride for ... RedOrbit Biovail Launches Glumetza to Canadian Physicians - Nov 29, 2005 Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today that it has officially launched Glumetza TM in Canada. Developed in partnership with Depomed, ... ccnmatthews.com Starwatch consumer - Sep 7, 2006 King Pharmaceuticals Inc. and Depomed Inc. said Glumetza, the type 2 diabetes drug, ... Glumetza will enable the companies to compete for metformin, ... $2.95 - Kansas City Star - NewsBank Depomed to Announce Third Quarter 2007 Financial Results on … - Nov 1, 2007 Glumetzaâ„¢ (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is being marketed in the United States ... businesswire.com … program offers savings on Glumetza.(LATEBREAKERS)(Brief article) - Dec 11, 2006 King Pharmaceuticals and Depomed have launched a savings program for diabetes patients who are receiving treatment with Glumetza (metformin HCl ... Free with registration - Drug Topics - AccessMyLibrary.com Diabetes Drug Glumetza Gets Approvable Letter From FDA - Apr 5, 2005 The FDA issued an approvable letter for Glumetza, a once-daily, extended-release version of the diabetes drug metformin. Though Glumetza is not yet cleared ... Diabetes In Control Depomed Completes $20 Million Registered Direct Offering - Apr 23, 2007 In addition, once daily Glumetza(TM) (metformin hydrochloride extended release tablets) has been approved for use in adults with type 2 diabetes and is ... Genetic Engineering News - Genetic Engineering News (press release) GLUMETZA DepoMed clinical data (diabetes). - Jun 12, 2006 On 11 April 2006, DepoMed reported results of a phase III trial of extended-release metformin (GLUMETZA), in the treatment of type II diabetes. ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones USA pharma: Santarus starts promotion of glumetza - Oct 15, 2008 San Diego, USA-based Santarus, a specialty pharmaceutical firm, says it has commenced promotion of Glumetza (metformin HCl), a once-daily, extended-release ... $34.00 - EIU Country Analysis - Alacra Store … ; FDA grants approvable letter for extended-release Glumetza for... - Mar 29, 2005 The letter indicated that Glumetza is approvable pending the completion of ... Biovail's NDA for Glumetza - in 500mg and 1000mg dosage forms - was filed ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Q2 2006 King Pharmaceuticals Earnings Conference Call - Part 1. - Aug 9, 2006 Additionally, this opportunity, coupled with our recent agreement with Depomed to co-promote Glumetza enables us to continue strengthening our presence in a ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Santarus to Present at Rodman & Renshaw 10th Annual Healthcare … - Oct 30, 2008 GLUMETZA(R) is a trademark of Biovail Laboratories International Srl licensed exclusively in the United States to Depomed, Inc. Santarus(R) and ZEGERID(R) ... RedOrbit Depomed Reports First Quarter 2006 Financial Results. - May 10, 2006 In addition, regulatory applications for once daily Glumetza(TM) for the treatment of Type II diabetes have been approved in the US and Canada. ... Free with registration - Business Wire - AccessMyLibrary.com Diabetes drug Glumetza gets approvable letter.(Wednesday, March 2)( … - Mar 7, 2005 The FDA issued an approvable letter for Glumetza, a once-daily, extended-release version of the diabetes drug metformin, driving up Depomed Inc.'s stock ... Free with registration - BioWorld Week - AccessMyLibrary.com Depomed Initiates Phase 3 Program In Menopausal Hot Flashes - Sep 19, 2008 GLUMETZA® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United ... Medical News Today - Medical News Today (press release) Q3 2007 Depomed Earnings Conference Call - Final. - Nov 1, 2007 As for GLUMETZA, with the termination of the King promotion agreement, ... Over the past year, we have taken GLUMETZA from the point where some may say it ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Depomed posts loss of $9.9M for Q2 - Aug 7, 2006 But Depomed (NASDAQ: DEPO) saw its operating costs grow because of development of another drug and expenses related to Glumetza. Operating expenses in the ... San Francisco Business Times International Approvals: Glumetza, 500-mg Invirase, Proxinium - Jun 6, 2005 June 6, 2005 -- The Canadian Therapeutic Products Directorate has approved a once-daily, extended-release formulation of metformin HCl for the treatment of ... Medscape … revise agreement for development, commercialization of Glumetza - Jan 10, 2006 Under the new agreement, Depomed will have the marketing and distribution rights to the 500 mg and 1000 mg formulations of Glumetza in the United States. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones News and Press release service TransWorldNews - Apr 11, 2006 The data demonstrated that Glumetza (extended-release metformin) controlled ... "We feel that Glumetza provides a unique formulation of metformin that ... TransWorldNews - TransWorldNews (press release) FDA approves Biovail's Glumetza.(Pharmaceutical industry)(Food and … - Mar 14, 2005 Canadian drugmaker Biovail Corp has received preliminary approval from the US Food and Drug Administration for two dose-strength preparations of its ... $4.95 - Pharma Marketletter - ECNext Q4 2005 DepoMed Earnings Conference Call - Final. - Mar 14, 2006 Glumetza was approved by both the Canadian and US regulatory agencies, ... At the end of 2005, Biovail launched Glumetza in Canada, separately for the US In ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Biovail, Depomed Receive Approvable Letter for Glumetza - Mar 8, 2005 Biovail and Depomed have received an approvable letter from the FDA regarding their new drug application for Glumetza, a once-daily, extended-release ... Pay-Per-View - FDAnews Drug Pipeline Alert - Factiva, from Dow Jones King Pharma and Depomed to co-promote Glumetza. - Jul 3, 2006 King Pharma and Depomed to co-promote Glumetza. King Pharmaceuticals and fellow US drugmaker Depomed have entered into a co-exclusive agreement to ... $9.94 - Pharma Marketletter - Alacra Store Biovail/Depomed: FDA approves Glumetza.(Brief Article) - Jun 13, 2005 Canadian drugmaker Biovail and the USA's Depomed have received approval from the US Food and Drug Administration for Glumetza (metformin HCl), a once-daily, ... Pay-Per-View - Pharma Marketletter - Factiva, from Dow Jones Glumetza for type 2 diabetes.(PRODUCTS)(Brief Article) | Article from... - Oct 1, 2005 Glumetza for type 2 diabetes.(PRODUCTS)(Brief Article) ... find Internal Medicine News articles. Glumetza (metformin HCI extended-release tablets) is ... Pay-Per-View - Internal Medicine News - HighBeam Research Glumetza. - Oct 23, 2006 Glumetza (metformin hydrochloride extended-release tablet) is now available from King Pharmaceuticals, Bristol, Tenn., (423) 989-2000, and Depomed Inc., ... $9.94 - Drug Topics - Alacra Store Biovail launches Glumetza in Canada.(hypoglycemic drug)(Brief Article) - Dec 5, 2005 Toronto, Canada-headquartered Biovail Corp says that it has officially launched the once-daily diabetes mellitus drug Glumetza onto the Canadian market. ... $4.95 - Pharma Marketletter - ECNext Glumetza.(NEW DRUGS)(Brief article) - Oct 23, 2006 Glumetza (metformin hydrochloride extended-release tablet) is now available from King Pharmaceuticals, Bristol, Tenn., (423) 989-2000, and Depomed Inc., ... $4.95 - Drug Topics - ECNext Depomed Provides Update on Esprit Pharma Agreement. - Jul 24, 2006 In addition, once daily Glumetza(TM) for the treatment of Type II diabetes has been approved and is currently being marketed in Canada. ... $4.95 - Business Wire - ECNext Depomed's revenue and loss rise in Q3 - Nov 9, 2006 Depomed's operating costs rose compared with last year, primarily because of its commercialization of its diabetes drug Glumetza and development of ... San Francisco Business Times Depomed Announces Extended Phase II Results for Furosemide GR in … - May 13, 2005 Regulatory applications for once daily Glumetza(TM) (Metformin GR) for the treatment ... Depomed has been notified that the NDA for Glumetza is approvable. ... $4.95 - Business Wire - ECNext Depomed Reports 2004 Year End Financial Results. - Mar 16, 2005 ..."I am particularly pleased with the filings of New Drug Applications for our two lead specialty pharmaceuticals, Glumetza and Proquin. For Glumetza, we have ... $4.95 - Business Wire - ECNext Depomedç³–å°¿ç—…è?¯ç‰©Glumetza获FDA批准 - Jan 2, 2008 ...ã€?MarketWatch伦敦1月2日讯】Depomed Inc.(DEPO)å‘¨ä¸‰å®£å¸ƒï¼Œå…¶ç ”åˆ¶çš„1000毫克剂é‡? çš„Glumetza片剂获得了美国食å“?å’Œè?¯å“?管ç?†å±€(FDA)的批准。 ... 新浪网 Depomed Delivers Notice of Breach to Biovail. - Oct 3, 2005 Glumetza was approved on May 31, 2005 by the Therapeutic Products ... Do not take Glumetza(TM) if you have kidney problems, heart failure that is treated ... $4.95 - Business Wire - ECNext UDL Holdings Ltd acquires Net Excel Management Ltd from Harbour … - Aug 1, 2008 Depomed re ported Glumetza net sales of $#.# million…Inc. announced that it will hold a conference call on August… METABOLIC ENDOCRINOLOGY TYPE II ... Pay-Per-View - deals - Alacra Store Depomed's PHN Pain Drug Falters In Phase III Attempt - Jul 11, 2007 In the US, Depomed already markets Glumetza, the once-daily form of metformin, ... based King Pharmaceuticals Inc., which started knocking on Glumetza ... BioWorld Online - BioWorld Online FINAL TRANSCRIPT - May 1, 2008 As for Glumetza prescriptions are maintaining a $25 million gross revenue run rate. Glumetza market share within the branded ... $54.00 - Thomson StreetEvents - Alacra Store Depomed Reports First Quarter 2007 Financial Results - May 8, 2007 Glumetza(TM) (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is being marketed in the United ... Genetic Engineering News - Genetic Engineering News (press release) Biovail et Depomed peuvent commercialiser le Glumetza - Jun 1, 2005 Biovail (BVF) et Depomed, deux entreprises biopharmaceutiques, ont reçu l'approbation des organismes de régulation canadiens en vue de commercialiser le ... Le Journal de Québec Contributing to the Fight against Diabetes is Only a Click Away... - Nov 15, 2006 Glumetza(TM) may be used concomitantly with a sulfonylurea or insulin to improve ... Glumetza(TM) is contraindicated in patients with renal disease or renal ... Genetic Engineering News - Genetic Engineering News (press release) King Pharmaceuticals Reports Second-Quarter 2006 Financial Results. - Aug 9, 2006 Glumetza(TM) is a once-daily, extended-release formulation of metformin HCl indicated as an adjunct to diet and exercise to improve glycemic control in ... Free with registration - Business Wire - AccessMyLibrary.com Depomed Reports Second Quarter 2007 Financial Results - Jun 30, 2007 Glumetza(TM) (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is being marketed in the United ... Genetic Engineering News - Genetic Engineering News (press release) Depomed Reports First Quarter 2005 Financial Results. - May 10, 2005 Regulatory applications for once daily Glumetza(TM) (Metformin GR(TM)) for the ... Depomed has been notified that the NDA for Glumetza is approvable. ... $4.95 - Business Wire - ECNext Business & Finance; Depomed reports second quarter revenues increase … - Sep 5, 2006 ..."Through our co-promotion agreement with King Pharmaceuticals, Inc. signed in June, we look forward to the launch of Glumetza in the US before the end of ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Santarus Q3 loss narrows on higher drug sales - Nov 3, 2008 ...'Our sales force has begun promoting Glumetza for the treatment of patients ... 'We anticipate the addition of Glumetza will be accretive in 2009 and beyond ... Forbes Merger and Acquisition Scenario - Jul 7, 2007 Furosemide GR; GERD Program; Glumetza (Metformin GR); Gabapentin GR ... Depomed has developed two commercial products: GLUMETZA (metformin hydrochloride ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jul 7, 2007 Furosemide GR; GERD Program; Glumetza (Metformin GR); Gabapentin GR ... Depomed has developed two commercial products: GLUMETZA (metformin hydrochloride ... $250.00 - Revere Reports - Revere Depomed Receives Million From Biovail - Health News - redOrbit - Jul 6, 2005 Recently, regulatory applications for Glumetza were approved in the United States and ... In addition, regulatory applications for once daily Glumetza(TM) ... RedOrbit Trial results for diabetes drug released. - Jun 12, 2006 The pharmaceutical company Depomed Inc., makers of Glumetza, ... In the Phase 3 trial, Depomed said Glumetza had 97 percent patient compliance because of ... Free with registration - UPI NewsTrack - AccessMyLibrary.com Depomed's Proquin XR Wins FDA Approval As Treatment For UTIs - May 23, 2005 That letter indicated that Glumetza is approvable pending discussions related ... Those near-term prospects offered by Proquin XR and Glumetza have Depomed ... BioWorld Online - BioWorld Online Extended-release formulation of metformin OK'd.(BREAKING NEWS ...)( … - Jun 20, 2005 The FDA recently approved Glumetza (Biovail), a once-daily, extended-release formulation of metformin that is indicated for the treatment of Type 2 diabetes ... Free with registration - Drug Topics - AccessMyLibrary.com Event Brief of Q2 2005 Biovail Corporation Earnings Conference Call -... - Aug 4, 2005 The FDA approved Glumetza in the US 2. A world class manufacturing capability continues to set BVF apart from many of its competitors. 9. In April: 1. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Merger and Acquisition Scenario - Jul 7, 2007 Furosemide GR; GERD Program; Glumetza (Metformin GR); Gabapentin GR ... Depomed has developed two commercial products: GLUMETZA (metformin hydrochloride ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jul 7, 2007 Furosemide GR; GERD Program; Glumetza (Metformin GR); Gabapentin GR ... Depomed has developed two commercial products: GLUMETZA (metformin hydrochloride ... $250.00 - Revere Reports - Revere Press Release: Stocks to Watch - DEPO, IBM, AMED, SEPR. - M2 … - Jan 2, 2008 We believe this 1000 mg dosage form is a great addition to the Glumetza franchise, as we now have two ways for patients to achieve 24-hour glycemic control: ... Pay-Per-View - M2 Presswire - HighBeam Research Finance; Proquin maker reports a net loss of $26.9 million in 2004 - Apr 11, 2005 ..."I am particularly pleased with the filings of new drug applications for our two lead specialty pharmaceuticals, Glumetza and Proquin. For Glumetza, we have ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones Merger and Acquisition Scenario - Jul 7, 2007 Furosemide GR; GERD Program; Glumetza (Metformin GR); Gabapentin GR ... Depomed has developed two commercial products: GLUMETZA (metformin hydrochloride ... $250.00 - Revere Reports - Revere Riomet said to make compliance easier.(Rx/Diabetes Care) | Article... - Mar 28, 2005 According to a spokeswoman for Depomed, Glumetza has been shown to be ... Biovail Corp. has launched Glumetza in Canada as a treatment for type 2 diabetes. ... Pay-Per-View - Chain Drug Review - HighBeam Research Merger and Acquisition Scenario - Jul 7, 2007 Furosemide GR; GERD Program; Glumetza (Metformin GR); Gabapentin GR ... Depomed has developed two commercial products: GLUMETZA (metformin hydrochloride ... $250.00 - Revere Reports - Revere Finance; Proquin maker reports a net loss of $26.9 million in 2004 - Apr 17, 2005 ..."I am particularly pleased with the filings of new drug applications for our two lead specialty pharmaceuticals, Glumetza and Proquin. For Glumetza, we have ... Pay-Per-View - Medical Letter on the CDC & FDA - Factiva, from Dow Jones Merger and Acquisition Scenario - Jul 7, 2007 Furosemide GR; GERD Program; Glumetza (Metformin GR); Gabapentin GR ... Depomed has developed two commercial products: GLUMETZA (metformin hydrochloride ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jul 15, 2006 Furosemide GR; Glumetza (Metformin GR); Metformin/Sulfonylurea GR ... Glumetza (Metformin GR). Research/Preclinical Stage Products ... $250.00 - Revere Reports - Revere Depomed Reports Second Quarter 2005 Financial Results. - Aug 9, 2005 ..."Through our partners, we expect both Glumetza and Proquin XR to be launched by ... In addition, regulatory applications for once daily Glumetza(TM) ... $4.95 - Business Wire - ECNext Merger and Acquisition Scenario - Jul 7, 2007 Furosemide GR; GERD Program; Glumetza (Metformin GR); Gabapentin GR ... Depomed has developed two commercial products: GLUMETZA (metformin hydrochloride ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jul 7, 2007 Furosemide GR; GERD Program; Glumetza (Metformin GR); Gabapentin GR ... Depomed has developed two commercial products: GLUMETZA (metformin hydrochloride ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jul 7, 2007 Furosemide GR; GERD Program; Glumetza (Metformin GR); Gabapentin GR ... Depomed has developed two commercial products: GLUMETZA (metformin hydrochloride ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jul 7, 2007 Furosemide GR; GERD Program; Glumetza (Metformin GR); Gabapentin GR ... Depomed has developed two commercial products: GLUMETZA (metformin hydrochloride ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - May 13, 2006 Furosemide GR; Glumetza (Metformin GR); Metformin/Sulfonylurea GR ... Glumetza (Metformin GR). Research/Preclinical Stage Products ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Apr 1, 2006 Furosemide GR; Glumetza (Metformin GR); Metformin/Sulfonylurea GR ... Glumetza (Metformin GR). Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Terminated deals boost Depomed profit - Mar 6, 2008 Total revenue for 2007 was $65.6 million, compared with $9.6 million for 2006. The company's 1000 mg Glumetza tablets won FDA approval in December. Bizjournals.com Diabetes drug raises heart safety concerns - Nov 9, 2007 Metformin is an anti-diabetic drug sold under the brand names Glucophage, Glumetza or in generic forms with "metformin" as part of the name. ... Pay-Per-View - The Record - ProQuest Archiver |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |